Last reviewed · How we verify
Comparator: vancomycin
Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Serious infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile-associated diarrhea and colitis, Endocarditis.
At a glance
| Generic name | Comparator: vancomycin |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Glycopeptide antibiotic |
| Target | D-Ala-D-Ala peptidoglycan precursor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Vancomycin works by binding to the D-alanyl-D-alanine terminus of nascent peptidoglycan in the bacterial cell wall, preventing cross-linking and causing cell wall instability. This leads to bacterial cell lysis and death. It is particularly effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
Approved indications
- Serious infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)
- Clostridium difficile-associated diarrhea and colitis
- Endocarditis
- Septicemia and other serious gram-positive infections
Common side effects
- Nephrotoxicity
- Ototoxicity
- Red man syndrome (flushing, pruritus)
- Phlebitis at infusion site
- Fever
- Chills
Key clinical trials
- Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection (PHASE2)
- Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis (PHASE2)
- Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients (PHASE2, PHASE3)
- A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) (PHASE3)
- ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection (PHASE2)
- Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA (PHASE3)
- Probiotic Efficacy in VRE Eradication (NA)
- Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: vancomycin CI brief — competitive landscape report
- Comparator: vancomycin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI